Credit Industriel ET Commercial Reduces Stock Position in Alumis Inc. $ALMS

Credit Industriel ET Commercial cut its stake in Alumis Inc. (NASDAQ:ALMS) by 36.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 247,002 shares of the company’s stock after selling 140,000 shares during the quarter. Credit Industriel ET Commercial’s holdings in Alumis were worth $986,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Orbimed Advisors LLC bought a new stake in Alumis in the 2nd quarter worth approximately $5,779,000. Velan Capital Investment Management LP purchased a new stake in Alumis during the second quarter valued at $4,863,000. Samsara Biocapital LLC grew its stake in shares of Alumis by 47.0% during the 2nd quarter. Samsara Biocapital LLC now owns 4,801,370 shares of the company’s stock valued at $14,404,000 after purchasing an additional 1,534,872 shares during the period. Tybourne Capital Management HK Ltd. purchased a new stake in shares of Alumis during the 2nd quarter valued at about $4,198,000. Finally, General Atlantic L.P. bought a new position in shares of Alumis in the 2nd quarter worth approximately $3,893,000.

Alumis Stock Performance

ALMS opened at $26.54 on Monday. The stock has a market cap of $2.77 billion, a price-to-earnings ratio of -6.55 and a beta of -2.13. The firm’s fifty day moving average is $18.74 and its 200 day moving average is $9.84. Alumis Inc. has a fifty-two week low of $2.76 and a fifty-two week high of $28.29.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.14). The business had revenue of $2.07 million during the quarter, compared to analyst estimates of $3.14 million. On average, equities research analysts predict that Alumis Inc. will post -8.51 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on ALMS shares. UBS Group restated an “outperform” rating on shares of Alumis in a research report on Tuesday, January 6th. HC Wainwright reiterated a “buy” rating and set a $40.00 price target (up previously from $20.00) on shares of Alumis in a research note on Friday, January 9th. Chardan Capital assumed coverage on Alumis in a research note on Wednesday, January 21st. They issued a “buy” rating and a $37.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alumis in a report on Monday, December 29th. Finally, Loop Capital set a $37.00 price target on Alumis in a report on Wednesday, January 21st. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $37.50.

Insiders Place Their Bets

In other Alumis news, major shareholder Foresite Capital Management Vi purchased 411,764 shares of the stock in a transaction that occurred on Thursday, January 8th. The shares were bought at an average cost of $17.00 per share, with a total value of $6,999,988.00. Following the acquisition, the insider owned 5,702,536 shares in the company, valued at approximately $96,943,112. This trade represents a 7.78% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Foresite Labs, Llc acquired 411,764 shares of the business’s stock in a transaction on Thursday, January 8th. The shares were bought at an average cost of $17.00 per share, with a total value of $6,999,988.00. Following the completion of the acquisition, the insider owned 5,702,536 shares in the company, valued at approximately $96,943,112. This represents a 7.78% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders have bought 3,735,309 shares of company stock worth $44,543,340. Company insiders own 40.70% of the company’s stock.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.